These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37089779)

  • 1. Correction to: A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.
    Open Forum Infect Dis; 2023 Apr; 10(4):ofad196. PubMed ID: 37089779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.
    Kim JY; Săndulescu O; Preotescu LL; Rivera-Martínez NE; Dobryanska M; Birlutiu V; Miftode EG; Gaibu N; Caliman-Sturdza O; Florescu SA; Shi HJ; Streinu-Cercel A; Streinu-Cercel A; Lee SJ; Kim SH; Chang I; Bae YJ; Suh JH; Chung DR; Kim SJ; Kim MR; Lee SG; Park G; Eom JS
    Open Forum Infect Dis; 2022 Aug; 9(8):ofac406. PubMed ID: 36043180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction.
    Open Forum Infect Dis; 2024 May; 11(5):ofae247. PubMed ID: 38737430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019.
    Streinu-Cercel A; Săndulescu O; Preotescu LL; Kim JY; Kim YS; Cheon S; Jang YR; Lee SJ; Kim SH; Chang I; Suh JH; Lee SG; Kim MR; Chung DR; Kim HN; Streinu-Cercel A; Eom JS
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac053. PubMed ID: 35295819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea.
    Hong SI; Ryu BH; Hong KW; Bae IG; Cho OH
    Infect Chemother; 2022 Mar; 54(1):114-124. PubMed ID: 35384423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit].
    Markina UA; Fomina DS; Lebedkina MS; Kruglova TS; Chernov AA; Zagrebneva AI; Mutovina ZY; Karaulov AV; Alexeeva EI; Lysenko MA
    Ter Arkh; 2022 Jun; 94(5):675-682. PubMed ID: 36286968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study.
    Park S; Je NK; Kim DW; Park M; Heo J
    J Korean Med Sci; 2022 Apr; 37(13):e102. PubMed ID: 35380027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study.
    Jang YR; Oh YJ; Kim JY
    Curr Ther Res Clin Exp; 2022; 96():100675. PubMed ID: 35601976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak.
    Lee CM; Park SW; Lee E
    Infect Chemother; 2022 Jun; 54(2):258-265. PubMed ID: 35706081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance.
    Kwak YG; Song JE; Kang J; Kang J; Kang HK; Koo HK; Park HK; Choi SB; Lee HP; Lee MJ; Kim BN
    Infect Chemother; 2022 Dec; 54(4):781-786. PubMed ID: 36226346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction to: Host Biomarkers Reflect Prognosis in Patients Presenting With Moderate Coronavirus Disease 2019: A Prospective Cohort Study.
    Open Forum Infect Dis; 2023 Apr; 10(4):ofad037. PubMed ID: 37082617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study.
    Lee S; Lee SO; Lee JE; Kim KH; Lee SH; Hwang S; Kim SW; Chang HH; Kim Y; Bae S; Kim AS; Kwon KT
    Int Immunopharmacol; 2022 May; 106():108570. PubMed ID: 35168079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease.
    Lee JY; Lee JY; Ko JH; Hyun M; Kim HA; Cho S; Lee YD; Song J; Shin S; Peck KR
    Front Immunol; 2021; 12():772320. PubMed ID: 34899724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction.
    Open Forum Infect Dis; 2023 Oct; 10(10):ofad489. PubMed ID: 37818341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant.
    Jang YR; Oh YJ; Kim JY
    Int J Infect Dis; 2023 May; 130():94-100. PubMed ID: 36623794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erratum.
    Open Forum Infect Dis; 2015 Jan; 2(1):ofv041. PubMed ID: 26161428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction to: Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients.
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac567. PubMed ID: 36324325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction to: Effect on the Resistome of Dual vs Monotherapy for the Treatment of Neisseria gonorrhoeae: Results From a Randomized Controlled Trial (ResistAZM Trial).
    Open Forum Infect Dis; 2024 Feb; 11(2):ofae104. PubMed ID: 38405680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction to: Effects of Internet Cognitive-Behavioral Therapy on Depressive Symptoms and Surrogates of Cardiovascular Risk in Human Immunodeficiency Virus: A Pilot, Randomized, Controlled Trial.
    Open Forum Infect Dis; 2023 Jun; 10(6):ofad310. PubMed ID: 37333723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regdanvimab: First Approval.
    Syed YY
    Drugs; 2021 Dec; 81(18):2133-2137. PubMed ID: 34724174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.